BriaCell TherapeuticsBCTXW 23 EBITDA Margin % is 0.00% as of Apr. 2026. GuruFocus rates BCTXW with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, BriaCell Therapeutics ranks worse than 105820% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BriaCell Therapeutics EBITDA Margin % Related Terms
BriaCell Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BriaCell Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCTXW vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, BriaCell Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BriaCell Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BriaCell Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BriaCell Therapeutics (BCTXW) has a EBITDA Margin % of 0.00% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BriaCell Therapeutics and its competitors. According to the industry distribution chart, BriaCell Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is BriaCell Therapeutics' EBITDA Margin % too high?
BriaCell Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, BriaCell Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BriaCell Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BriaCell Therapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BriaCell Therapeutics ranks #999999 out of 945 companies for EBITDA Margin %. This places BriaCell Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BriaCell Therapeutics and its competitors. BriaCell Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BriaCell Therapeutics stock overvalued right now?
BriaCell Therapeutics (BCTXW) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. BriaCell Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BriaCell Therapeutics (BCTXW), the current EBITDA Margin % is 0.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
23GF Score
Get the complete analysis for BCTXW
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCTXW has been successfully added to your 
